Lisdexamfetamine: 5 agencies, 2013–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused lisdexamfetamine: all 10 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 12.4 years separate the first record, 13 May 2013 at SMC (Scotland), from the most recent, 8 Oct 2025 at HAS (France).
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 2 of 10 records date from 2023 or later.
Against its own class, lisdexamfetamine is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class N06B average 65%.
3 distinct indication wordings are recorded for lisdexamfetamine by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 10 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess lisdexamfetamine, on 13 May 2013; HAS (France) did not open a file until 8 Oct 2025 — an unusually long tail of 12.4 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
4 of the 5 agencies here assessed lisdexamfetamine more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed lisdexamfetamine.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Attention deficit hyperactivity disorder (ADHD) | Recommended | source |
| PHARMAC (New Zealand) | 6 Dec 2021 | Attention Deficit Hyperactivity Disorder (ADHD) | PTAC advice: Cost Neutral | source |
| PHARMAC (New Zealand) | 6 Dec 2021 | Attention Deficit Hyperactivity Disorder (ADHD) | PTAC advice: Cost Neutral · decision reached | source |
| AWMSG (Wales) | 13 Oct 2015 | As part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults | recommended (full) | source |
| SMC (Scotland) | 7 Sep 2015 | Indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. | accepted | source |
5 further decisions for lisdexamfetamine, across 4 agencies, are not shown here. They include the most recent record on file, 8 Oct 2025 from HAS (France); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- guanfacine — divergent outcome (recommended vs not recommended) on a shared indication
- methylphenidate — same ATC class N06B — Psychoanaleptics
- idebenone — same ATC class N06B — Psychoanaleptics
- solriamfetol — same ATC class N06B — Psychoanaleptics
- piracetam — same ATC class N06B — Psychoanaleptics
- modafinil — same ATC class N06B — Psychoanaleptics
Coverage: 10 decisions for lisdexamfetamine from 5 agencies, 2013 to 2025. Data to 7 Sep 2026. ATC class N06B — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.